Kymera reports Q3 net loss $52.9M; initiates Phase 2 HS trial, receives $40M milestone

Kymera Therapeutics, Inc.

2023-Q3 EPS reported -$2.27 revenue$30,707,000

Net loss of $52.9M in Q3 2023 vs $43.0M loss in Q3 2022; revenue $4.7M down from $9.6M.
First patient dosed in KT-474 (IRAK4) Phase 2 HS trial triggered $40M milestone from Sanofi; Phase 2 AD dosing expected Q4 2023.
KT-333 (STAT3) Phase 1 shows partial response in CTCL patient; Fast Track granted for CTCL/PTCL.
KT-253 (MDM2) achieved proof-of-mechanism; confirmed partial response in Merkel cell carcinoma patient.
KT-413 (IRAKIMiD) development discontinued; cash $435M provides runway into H1 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kymera Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 2, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-268815

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.